Table 3.
DAA therapy and viral monitoring
| Survey Question | Response, n (%) |
| If you accept kidneys from donors who are HCV Ab+/NAT+ for recipients who are HCV−, when do you typically start DAA therapy? (item denominator=72 a ) | |
| Before transplant (on admission or en route) | 5 (7) |
| After transplant, but before discharge | 10 (14) |
| After discharge, but within 4 wk | 10 (14) |
| After discharge, only if HCV viremic | 38 (53) |
| Other | 9 (13) |
| If you accept kidneys from donors who are HCV Ab+/NAT+ for recipients who are HCV−, how long do you believe it is safe to wait to start DAA therapy? (item denominator=68 a ) | |
| At time of transplant | 6 (9) |
| After transplant, but before discharge | 8 (12) |
| After discharge but within 2 wk, regardless of HCV viremia | 6 (9) |
| After discharge but within 4 wk, regardless of HCV viremia | 11 (16) |
| After discharge but only if HCV viremic | 32 (47) |
| Other | 5 (7) |
| How often would you test a recipient of HCV Ab+/NAT+ donor kidney for HCV RNA after transplantation and appropriate 12 wk of DAA therapy? (item denominator=70 a ) | |
| Day 0, post-KTx day 1; DAA treatment weeks 1, 2, 3, 4, 8, and 12; after DAA treatment, continue testing at weeks 2, 4, 8, and 12 | 13 (19) |
| Day 0, post-KTx day 1; and at DAA treatment weeks 1, 2, 3, 4, 8, and 12 | 8 (11) |
| Post-KTx day 1, weekly during DAA treatment for 12 wk | 7 (10) |
| DAA treatment weeks 4, 8, and 12 | 11 (16) |
| DAA treatment weeks 4 and 12 | 6 (9) |
| Post-KTx day 1 and at the end of 12 wk of DAA treatment | 1 (1) |
| Other | 14 (20) |
| Unsure | 10 (14) |
| If your program performs a transplant from a donor who is HCV Ab+/NAT+ into a recipient who is HCV− and the patient’s insurance declines DAA therapy, do you have an institutional plan to provide a complete course of medication? (item denominator=71 a ) | |
| No | 11 (15) |
| Yes, from the transplant hospital | 40 (56) |
| Yes, through a pharmaceutical company (e.g., grant, research) | 4 (6) |
| Yes, through organ procurement organization | 0 (0) |
| Yes, through the department of surgery or department of medicine | 2 (3) |
| Other | 11 (15) |
| Unsure | 3 (4) |
Programs that reported not conducting transplant from donors who were HCV Ab+/NAT+ were omitted. DAA, direct-acting antiviral agent; HCV, hepatitis C virus; Ab, antibody; NAT, nucleic acid testing; KTx, kidney transplant.
a
Indicates the item denominator, based on number of respondents, and accounting for contingent responses.